Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome

ObjectiveTo examine the effects of fenofibrate (160 mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia.Research design and methodsRandomized, double-blind, controlled trial that compared the effects of 3-month therapy with placebo and fenofibrate on fasting and postprandial cytokine production in 55 subjects with metabolic syndrome and elevated fasting triglycerides (≥1.7 and <6.78 mmol/L).ResultsFenofibrate treatment reduced concentrations of monohydroxy fatty acids (OH-FA) by 15.5% (p = 0.001), lipopolysaccharide activated monocyte chemotactic protein-1 (MCP-1/CCL2) production in fasting blood samples by 3.4% (p = 0.01 vs. placebo), macrophage inflammatory protein-1α (MIP-1α/CCL3) by 3.5% (p = 0.01), and interleukin-1β (IL-1β) by 2.5% (p = 0.04). After a standardized fat load (50 kg/m2), OH-FA were reduced by 31.0% (p < 0.0001), MCP-1/CCL2 was reduced by 5.2% (p = 0.002), MIP-1α/CCL3 by 3.9% (p = 0.007), and IL-1β by 3.4% (p = 0.02). Reductions in MCP-1/CCL2, MIP-1α/CCL3, and IL-1β production correlated with changes in fasting and postprandial large very low-density lipoprotein (VLDL) (all p < 0.005) and small low-density lipoprotein (LDL) particles (all p < 0.05). In stepwise regression models that included age, gender, weight change, and drug assignment, large VLDL particles were associated with reductions in postprandial MCP-1/CCL2 (p = 0.042), MIP-1α/CCL3 (p = 0.003), and IL-1β (p = 0.02).ConclusionsThis study reports that fenofibrate reduces whole blood production of inflammatory cytokines and hepatic-synthesized inflammatory proteins, and the anti-inflammatory effects of fenofibrate therapy involve VLDL- and LDL-mediated pathways.